Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute. Learn more about Cancer Currents.
-
Some Women Avoid Breast Cancer Screening After False-Positive Mammogram ResultsSome women who receive a false-positive result on a mammogram may not come back for routine breast cancer screening in the future, a new study finds. Better doctor–patient communication about the screening process is needed, several researchers said.
-
Combination Chemo Helps People with Leiomyosarcoma Live LongerResults from a French clinical trial have identified what experts say should now be the recommended initial treatment of advanced leiomyosarcoma. In the trial, the combination of trabectedin (Yondelis) and doxorubicin improved survival by a median of 9 months.
-
Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once ThoughtOsteonecrosis of the jaw was thought to be a rare side effect of drugs like denosumab (Xgeva) that lessen bone problems when cancer has spread to the bone. But a new study has found that the painful side effect is more common than once thought.
-
Breast Cancer May Spread by Recruiting Nearby Sensory NervesA new study may provide important new insights into breast cancer metastasis. Blood vessels within tumors release a molecule that draws sensory nerves closer to the tumors, the study shows. This close proximity turns on genes in the cancer cells that drive metastasis.
-
Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal Stromal TumorsTrial participants who stopped imatinib had a more rapid worsening of disease, a shorter time until resistance, and did not live as long as participants who continued the therapy uninterrupted.
-
Study Identifies Hundreds of Potential Targets for Cancer DrugsResearchers have identified hundreds of promising targets for existing drugs or potential new cancer drugs. The findings relied heavily on proteogenomic data from more than 1,000 tumors representing 10 types of cancer released last year by NCI's CPTAC program.
-
DNA from Ancient Viruses Helps Many Cancers GrowDNA fragments from retroviruses that are millions of years old appear to be active in a variety of cancers, a new study found. One virus-derived DNA fragment in particular, known as LTR10, turns on cancer-related genes in multiple types of cancer.
-
Growing the Cancer Research Pipeline by Expanding OpportunitiesNCI Director Dr. Kimryn Rathmell and Division of Cancer Biology Director Dr. Dan Gallahan explain how the R15 grant program supports researchers at smaller institutions and encourages students to pursue careers in cancer research.
-
FDA Approves Engineered Cell Therapy for Advanced Synovial SarcomaFDA approved afami-cel (Tecelra) to treat metastatic synovial sarcoma, a type of soft tissue sarcoma. The approval is for patients who have already received chemo and whose tumors are positive for MAGE-A4. Afami-cel is the first T-cell receptor therapy approved for cancer.
-
To Combat Cancer Treatment Resistance, Researchers Try Leveraging EvolutionScientists have developed a strategy for treating cancer that takes advantage of tumors’ ability to rapidly evolve and turns it against them. It involves intentionally making some tumor cells resistant to a specific treatment from the get-go.
-
Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?Two new studies in mice show that adding chemotherapy to the experimental KRAS inhibitor MRTX1133 greatly reduced tumor growth and spread compared with either treatment alone.
-
New on NCI’s Websites for August 2024NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of August 2024.
-
Understanding the Risk of Second Cancers After CAR T-Cell TherapyIn late 2023, FDA announced it was investigating instances of second cancers following treatment with CAR T-cell therapies. In this Q&A, NCI’s Dr. Stephanie Goff explains what’s known about the issue, stressing that second cancers “of any kind are rare.”
-
Drug Combo JAKs Up Immunotherapy in Two Clinical TrialsScientists have been searching for ways to make immune checkpoint inhibitors work for more patients. In two trials, researchers explored a possible role for JAK inhibitors, which dampen chronic inflammation.
-
More Immunotherapy Options Approved for Treating Endometrial CancerPeople with advanced endometrial cancer now have new FDA-approved treatment options: pembrolizumab and durvalumab, paired with chemotherapy, for tumors with a genetic change called mismatch repair deficiency. The agency also expanded the approved uses of dostarlimab for the disease.
-
Screening People at High Risk for Pancreatic Cancer May Help Them Live LongerRegular imaging tests to monitor the pancreas may help detect pancreatic cancer at an early stage in people who are at high risk, a new study suggests. This type of surveillance could also help improve how long these patients live.
-
FDA Approves HPV Tests That Allow for Self-Collection in a Health Care SettingThe expanded approval of two HPV tests allows the patient to collect a vaginal sample themselves in a health care setting, rather than a health provider collecting a sample during a pelvic exam. The availability of a self-collection option in health care settings could help widen access to cervical cancer screening.
-
Treating the Whole Person: How Cancer Centers Are Addressing Social NeedsWhile treating people’s health-related social needs has always been a part of health care in one form or other, cancer centers and community cancer clinics increasingly are viewing the people they treat through a social lens and addressing social needs—including transportation, food, and housing—as part of patient care.
-
Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain MetastasesLorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also helped prevent new brain metastases.
-
Trial Establishes Preferred Treatment for Some People with Esophageal CancerFor people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with the CROSS regimen.